- Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
- Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Ultimovacs ASA – Annual General Meeting held on April 18, 2024
- Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program
- Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
- Ultimovacs – Invitation to Business Update on April 17, 2024
- Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Ultimovacs ASA: Notice of Annual General Meeting on April 18, 2024
- Ultimovacs ASA: Mandatory notification of trade by primary insider
More ▼
Key statistics
As of last trade, Ultimovacs ASA (ULTI:OSL) traded at 7.03, 15.82% above the 52 week low of 6.07 set on Mar 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.28 |
---|---|
High | 7.30 |
Low | 6.92 |
Bid | 7.03 |
Offer | 7.20 |
Previous close | 7.29 |
Average volume | 557.05k |
---|---|
Shares outstanding | 34.41m |
Free float | 23.73m |
P/E (TTM) | -- |
Market cap | 241.87m NOK |
EPS (TTM) | -5.50 NOK |
Data delayed at least 15 minutes, as of May 08 2024.
More ▼